LPL Financial LLC Has $6.50 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares of the biotechnology company’s stock after purchasing an additional 5,895 shares during the quarter. LPL Financial LLC’s holdings in Sarepta Therapeutics were worth $6,497,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Swedbank AB acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth $16,706,000. Allspring Global Investments Holdings LLC lifted its position in shares of Sarepta Therapeutics by 16,717.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 84,926 shares during the last quarter. Erste Asset Management GmbH boosted its stake in Sarepta Therapeutics by 11.3% in the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company’s stock valued at $86,116,000 after buying an additional 72,183 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Sarepta Therapeutics by 88.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 147,236 shares of the biotechnology company’s stock valued at $17,902,000 after acquiring an additional 68,992 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SRPT. Needham & Company LLC dropped their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a report on Thursday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. Royal Bank of Canada cut shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $161.00 to $87.00 in a research note on Monday, March 31st. HC Wainwright upgraded Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price target for the company in a research note on Wednesday, April 2nd. Finally, Scotiabank reduced their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research report on Thursday, March 20th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $163.18.

Sarepta Therapeutics Trading Down 7.1 %

Shares of SRPT stock opened at $54.43 on Monday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market capitalization of $5.28 billion, a price-to-earnings ratio of 43.54 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 52-week low of $54.26 and a 52-week high of $173.25. The company has a 50-day simple moving average of $96.95 and a two-hundred day simple moving average of $113.62.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.